190 related articles for article (PubMed ID: 17875870)
41. Type III juvenile pityriasis rubra pilaris: a successful treatment with infliximab.
Ruzzetti M; Saraceno R; Carboni I; Papoutsaki M; Chimenti S
J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):117-8. PubMed ID: 18181990
[No Abstract] [Full Text] [Related]
42. An unusual presentation of idiopathic hypereosinophilic syndrome.
Thakral C
Clin Adv Hematol Oncol; 2013 May; 11(5):320-1. PubMed ID: 23880718
[No Abstract] [Full Text] [Related]
43. Treatment of pityriasis amiantacea with infliximab.
Pham RK; Chan CS; Hsu S
Dermatol Online J; 2009 Dec; 15(12):13. PubMed ID: 20040263
[No Abstract] [Full Text] [Related]
44. How I treat hypereosinophilic syndromes.
Klion AD
Blood; 2009 Oct; 114(18):3736-41. PubMed ID: 19692700
[TBL] [Abstract][Full Text] [Related]
45. Hypereosinophilic syndrome and mepolizumab.
Boucher RM; Gilbert-McClain L; Chowdhury B
N Engl J Med; 2008 Jun; 358(26):2838-9; author reply 2839-40. PubMed ID: 18579821
[No Abstract] [Full Text] [Related]
46. Idiopathic hypereosinophilic syndrome associated with rapid progression of cardiac, pulmonary and skin infiltration.
He YQ; Zhu JM; Tong YL; Zeng H; Yang P
Cardiovasc J Afr; 2020; 31(5):274-280. PubMed ID: 32555925
[TBL] [Abstract][Full Text] [Related]
47. Treatment-refractory idiopathic hypereosinophilic syndrome: pitfalls and progress with use of novel drugs.
Bleeker JS; Syed FF; Cooper LT; Weiler CR; Tefferi A; Pardanani A
Am J Hematol; 2012 Jul; 87(7):703-6. PubMed ID: 22367886
[No Abstract] [Full Text] [Related]
48. Sarcoid sacroiliitis: successful treatment with infliximab.
Agrawal S; Bhagat S; Dasgupta B
Ann Rheum Dis; 2009 Feb; 68(2):283. PubMed ID: 19139204
[No Abstract] [Full Text] [Related]
49. The case of SLE associated Sneddon-Wilkinson pustular disease successfully and safely treated with infliximab.
Naretto C; Baldovino S; Rossi E; Spriano M; Roccatello D
Lupus; 2009 Aug; 18(9):856-7. PubMed ID: 19578113
[No Abstract] [Full Text] [Related]
50. What is the rate of loss of response to infliximab therapy in Crohn's disease?
Chao J; Mulani P
Am J Gastroenterol; 2009 Sep; 104(9):2353-4; author reply 2354-5. PubMed ID: 19727093
[No Abstract] [Full Text] [Related]
51. Hypereosinophilic syndrome and mepolizumab.
Verzegnassi F
N Engl J Med; 2008 Jun; 358(26):2838; author reply 2839-40. PubMed ID: 18584819
[No Abstract] [Full Text] [Related]
52. Cutaneous metastatic Crohn's disease responsive to infliximab.
Petrolati A; Altavilla N; Cipolla R; Fenderico P; Forlini G; Nasoni S; Rossi Z
Am J Gastroenterol; 2009 Apr; 104(4):1058. PubMed ID: 19259072
[No Abstract] [Full Text] [Related]
53. Common variable immunodeficiency and granulomatosis treated with infliximab.
Malbrán A; Juri MC; Fernández Romero DS
Clin Immunol; 2010 Mar; 134(3):359-60. PubMed ID: 20018565
[No Abstract] [Full Text] [Related]
54. Recent advances in pathogenesis and management of hypereosinophilic syndromes.
Roufosse F; Cogan E; Goldman M
Allergy; 2004 Jul; 59(7):673-89. PubMed ID: 15180753
[TBL] [Abstract][Full Text] [Related]
55. What is the association between the tumor necrosis factor-alpha inhibitor infliximab and complex regional pain syndrome type I?
Paraskevas KI
Paediatr Anaesth; 2008 Jul; 18(7):689-90. PubMed ID: 18331547
[No Abstract] [Full Text] [Related]
56. Colectomy rate in acute severe ulcerative colitis in the infliximab era.
Aratari A; Papi C; Clemente V; Moretti A; Luchetti R; Koch M; Capurso L; Caprilli R
Dig Liver Dis; 2008 Oct; 40(10):821-6. PubMed ID: 18472316
[TBL] [Abstract][Full Text] [Related]
57. Infliximab: a promising alternative therapy for refractory arthritis/urethritis/conjunctivitis triad.
de Carvalho JF; Ribeiro AC; de Moraes JC; Gonçalves C; Goldenstein-Schainberg C; Bonfá E
Isr Med Assoc J; 2009 Aug; 11(8):511-3. PubMed ID: 19891245
[No Abstract] [Full Text] [Related]
58. Palmoplantar pustulosis and acrodermatitis in a patient treated with infliximab for Crohn's sacroiliitis.
Wermuth J; Kind F; Steuerwald M
Clin Gastroenterol Hepatol; 2009 Feb; 7(2):A28. PubMed ID: 19187898
[No Abstract] [Full Text] [Related]
59. Infliximab for patients with plaque psoriasis and severe psychiatric comorbidity.
Bassukas ID; Hyphantis T; Gamvroulia C; Gaitanis G; Mavreas V
J Eur Acad Dermatol Venereol; 2008 Feb; 22(2):257-8. PubMed ID: 18211435
[No Abstract] [Full Text] [Related]
60. Long-term efficacy of infliximab treatment for AA-amyloidosis secondary to chronic inflammatory arthritis.
Keersmaekers T; Claes K; Kuypers DR; de Vlam K; Verschueren P; Westhovens R
Ann Rheum Dis; 2009 May; 68(5):759-61. PubMed ID: 19366896
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
